Skip to main content
SpringerLink
Log in

Correlation between overexpression of EpCAM in prostate tissues and genesis of androgen-dependent prostate cancer

  • Research Article
  • Published:
Tumor Biology

Abstract

The objective of this study was to investigate the role of epithelial cell adhesion molecule (EpCAM) in the genesis and the progress of prostate cancer, especially of castration-resistant prostate cancer. Protein expression of EpCAM in ten pairs of prostate cancer tissues and normal adjacent tissues, plus three cell lines, was examined. Short hairpin RNA (shRNA) interference technique was employed to silence the expression of EpCAM in prostate cancer cell LNCaP and construct a stable transfected cell line. In vitro assay was conducted to analyze the effect of EpCAM expression on the expressions of Androgen receptor (AR), Prostate specific antigen (PSA), and cellular proliferation and invasion. EpCAM was found significantly expressed higher in prostate cancer tissues than in normal adjacent tissues. In three cell lines (DU-145, PC-3, and LNCaP), the expression of EpCAM in LNCaP, androgen-dependent prostate cancer cells, was significantly higher than that in the other two. As EpCAM was silenced in LNCaP, the expression levels of AR and PSA obviously descended, and cellular abilities of proliferation and invasion were obviously inhibited.The overexpression of EpCAM has correlation with the genesis of prostate cancer, especially androgen-dependent prostate cancer. As the expression of AR is facilitated, prostate cancer cells’ abilities to proliferate and invade are consequently enhanced.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Calabrò F, Sternberg CN. Current indications for chemotherapy in prostate cancer patients. Eur Urol. 2007;51(1):17–26.

    Article  PubMed  Google Scholar 

  2. Higano CS, Crawford ED. New and emerging agents for the treatment of castration-resistant prostate cancer. Urol Oncol. 2011;29(6 Suppl):S1–8.

    Article  CAS  PubMed  Google Scholar 

  3. Petrylak DP. Future directions in the treatment of androgen-independent prostate cancer. Urology. 2005;65(6 Suppl):8–12.

    Article  PubMed  Google Scholar 

  4. Baeuerle PA, Gires O. EpCAM (CD326) finding its role in cancer. Br J Cancer. 2007;96(3):417–23.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  5. Patriarca C, Macchi RM, Marschner AK, Mellstedt H. Epithelial cell adhesion molecule expression (CD326) in cancer: a short review. Cancer Treat Rev. 2012;38(1):68–75.

    Article  CAS  PubMed  Google Scholar 

  6. Kimura H, Kato H, Faried A, Sohda M, Nakajima M, Fukai Y, et al. Prognostic significance of EpCAM expression in human esophageal cancer. Int J Oncol. 2007;30(1):171–9.

    CAS  PubMed  Google Scholar 

  7. Trzpis M, McLaughlin PM, de Leij LM, Harmsen MC. Epithelial cell adhesion molecule: more than a carcinoma marker and adhesion molecule. Am J Pathol. 2007;171(2):386–95.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  8. van der Gun BT, Melchers LJ, Ruiters MH, de Leij LF, McLaughlin PM, Rots MG. EpCAM in carcinogenesis: the good, the bad or the ugly. Carcinogenesis. 2010;31(11):1913–21.

    Article  PubMed  Google Scholar 

  9. Spizzo G, Went P, Dirnhofer S, Obrist P, Simon R, Spichtin H, et al. High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer. Breast Cancer Res Treat. 2004;86(3):207–13.

    Article  CAS  PubMed  Google Scholar 

  10. Went P, Vasei M, Bubendorf L, Terracciano L, Tornillo L, Riede U, et al. Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. Br J Cancer. 2006;94(1):128–35.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  11. Poczatek RB, Myers RB, Manne U, Oelschlager DK, Weiss HL, Bostwick DG, et al. Ep-Cam levels in prostatic adenocarcinoma and prostatic intraepithelial neoplasia. J Urol. 1999;162(4):1462–6.

    Article  CAS  PubMed  Google Scholar 

  12. Zellweger T, Ninck C, Bloch M, Mirlacher M, Koivisto PA, Helin HJ, et al. Expression patterns of potential therapeutic targets in prostate cancer. Int J Cancer. 2005;113(4):619–28.

    Article  CAS  PubMed  Google Scholar 

  13. Benko G, Spajić B, Krušlin B, Tomas D. Impact of the EpCAM expression on biochemical recurrence-free survival in clinically localized prostate cancer. Urol Oncol. 2013;31(4):468–74.

    Article  CAS  PubMed  Google Scholar 

  14. Dehm SM, Tindall DJ. Regulation of androgen receptor signaling in prostate cancer. Expert Rev Anticancer Ther. 2005;5(1):63–74.

    Article  CAS  PubMed  Google Scholar 

  15. Li Y, Hwang TH, Oseth LA, Hauge A, Vessella RL, Schmechel SC, et al. AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression. Oncogene. 2012;31(45):4759–67.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  16. Grossmann ME, Huang H, Tindall DJ. Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst. 2001;93(22):1687–97.

    Article  CAS  PubMed  Google Scholar 

  17. Eskander RN, Tewari KS. Epithelial cell-adhesion molecule-directed trifunctional antibody immunotherapy for symptom management of advanced ovarian cancer. Clin Pharmacol. 2013;5 Suppl 1:55–61.

    PubMed Central  PubMed  Google Scholar 

  18. Hao H, Zhen Y, Wang Z, Chen F, Xie X. A novel therapeutic drug for colon cancer: EpCAM scFv-truncated protamine (tp)-siRNA. Cell Biol Int. 2013;37(8):860–4.

    Article  CAS  PubMed  Google Scholar 

  19. Gires O, Bauerle PA. EpCAM as a target in cancer therapy. J Clin Oncol. 2010;28(15):e239–40.

    Article  PubMed  Google Scholar 

  20. Gutheil JC. Novel immunologic and biologic therapies for breast cancer. Curr Oncol Rep. 2000;2(6):582–6.

    Article  CAS  PubMed  Google Scholar 

  21. Sun W, Haller DG. Adjuvant therapy of colon cancer. Semin Oncol. 2005;32(1):95–102.

    Article  CAS  PubMed  Google Scholar 

  22. Frampton JE. Catumaxomab: in malignant ascites. Drugs. 2012;72(10):1399–410.

    Article  CAS  PubMed  Google Scholar 

Download references

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China

    Yuan Xu & Jianquan Hou

  2. Department of Urology, Jiangsu Jiangyin People’s Hospital, Jiangyin, 214400, China

    Yuan Xu & Hu Zhao

Authors
  1. Yuan Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hu Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jianquan Hou
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jianquan Hou.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Xu, Y., Zhao, H. & Hou, J. Correlation between overexpression of EpCAM in prostate tissues and genesis of androgen-dependent prostate cancer. Tumor Biol. 35, 6695–6700 (2014). https://doi.org/10.1007/s13277-014-1892-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-014-1892-2

Keywords

Search

Navigation